Windlas Biotech Limited
“Debt-free CDMO quietly lapping generics complexity.”
Market view
our read, in one sentence, with the evidence one tap awayEODconviction recomputed 11:08No clear market view today
The signals we track (volume, delivery, price trend, deals, breadth and flows) aren't aligned for WINDLAS today. That isn't bearish, just inconclusive.
Why now
today's active factors, delivery data and signals worth reviewingTrading near 52-week high
50-day SMA is above 200-day SMA (bullish long-term trend)
Safety checks
India-specific risk checks.
Activity
filings, bulk and block deals, earnings and other events around this stockBusiness quality
the company itself, each lens scored and explained: a separate read from the Market Setup aboveEODfundamentals to FY27 Q1Strong business quality
Four fundamentals lenses on the company itself: valuation, growth, returns & margins, and financial health, judged against the stock's sector. A separate read from the Market Setup above.
Valuations look stretched
₹1,000 invested here buys about ₹28 of annual profit. A cheaper stock would buy more.
Strong revenue and profit growth
Excellent returns and margins
Strong balance sheet
Financials
income, balance sheet, cash flow, dividends and corporate actionsEODaudited to FY27Concalls
management commentary from earnings calls, summarisedEODlatest call 14 Aug '26Filings
exchange disclosures summarised as they are filed✦ AI summary: about 30s after the exchangePeers
how the stock stacks up against its closest listed comparablesEODprices end-of-dayData as of 18 Sept 2026, 11:08 am